ID   SU-DHL-2
AC   CVCL_9550
SY   SUDHL2; SUDHL-2; Su-DHL-2; SU-DHL2; SuDHL 2; Stanford University-Diffuse Histiocytic Lymphoma-2; DHL-2
DR   BTO; BTO:0006463
DR   EFO; EFO_0007611
DR   ATCC; CRL-2956
DR   ChEMBL-Cells; CHEMBL4523529
DR   ChEMBL-Targets; CHEMBL4523560
DR   Cosmic; 1289989
DR   Cosmic; 1486588
DR   Cosmic; 1517653
DR   Cosmic; 1550339
DR   Cosmic; 1636686
DR   Cosmic; 2361374
DR   DSMZ; ACC-902
DR   DSMZCellDive; ACC-902
DR   ENCODE; ENCBS354PZC
DR   ENCODE; ENCBS446LEC
DR   ENCODE; ENCBS621PAH
DR   ENCODE; ENCBS775VGT
DR   GEO; GSM1374905
DR   PubChem_Cell_line; CVCL_9550
DR   Wikidata; Q54970715
RX   PubMed=83902;
RX   PubMed=214220;
RX   PubMed=371794;
RX   PubMed=3881165;
RX   PubMed=4140017;
RX   PubMed=8547074;
RX   PubMed=15356658;
RX   PubMed=21179087;
CC   Population: Caucasian.
CC   Doubling time: ~24 hours (DSMZ=ACC-902).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Ser209Arg (c.627T>G) (p.Ser222Arg, c.666T>G) (S222R); Zygosity=Heterozygous (PubMed=21179087).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 14
ST   D18S51: 11
ST   D19S433: 12
ST   D21S11: 30
ST   D2S1338: 17,24
ST   D3S1358: 14,19
ST   D5S818: 13
ST   D7S820: 11,13
ST   D8S1179: 13
ST   FGA: 21,26
ST   Penta D: 13
ST   Penta E: 7,11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   73Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 25
//
RX   PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::AID-CNCR2820430102>3.0.CO;2-M;
RA   Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.;
RT   "Biology and virology of the human malignant lymphomas: 1st Milford D.
RT   Schulz Lecture.";
RL   Cancer 43:1-24(1979).
//
RX   PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4;
RA   Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. IV. Functional
RT   characterization of ten diffuse histiocytic lymphoma cell lines.";
RL   Cancer 42:2379-2391(1978).
//
RX   PubMed=371794;
RA   Epstein A.L., Kaplan H.S.;
RT   "Feeder layer and nutritional requirements for the establishment and
RT   cloning of human malignant lymphoma cell lines.";
RL   Cancer Res. 39:1748-1759(1979).
//
RX   PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
RX   PubMed=4140017; DOI=10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4;
RA   Epstein A.L., Kaplan H.S.;
RT   "Biology of the human malignant lymphomas. I. Establishment in
RT   continuous cell culture and heterotransplantation of diffuse
RT   histiocytic lymphomas.";
RL   Cancer 34:1851-1872(1974).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=15356658; DOI=10.1038/sj.leu.2403465;
RA   Drexler H.G., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   anaplastic large-cell lymphoma.";
RL   Leukemia 18:1569-1571(2004).
//
RX   PubMed=21179087; DOI=10.1038/nature09671;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. III, Romesser P.,
RA   Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G.,
RA   Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//